Amyris Inc (AMRS) Expected to Post Quarterly Sales of $100.76 Million

Brokerages forecast that Amyris Inc (NASDAQ:AMRS) will report $100.76 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Amyris’ earnings, with the highest sales estimate coming in at $103.00 million and the lowest estimate coming in at $98.52 million. Amyris reported sales of $80.59 million in the same quarter last year, which would suggest a positive year over year growth rate of 25%. The business is expected to issue its next quarterly earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Amyris will report full-year sales of $161.84 million for the current year, with estimates ranging from $159.57 million to $164.10 million. For the next financial year, analysts anticipate that the firm will post sales of $237.56 million, with estimates ranging from $225.22 million to $249.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Amyris.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.96). The firm had revenue of $14.90 million for the quarter, compared to analysts’ expectations of $46.72 million. Amyris’s quarterly revenue was down 38.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.81) EPS.

AMRS has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Amyris from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Amyris in a research report on Tuesday, August 7th. Zacks Investment Research lowered shares of Amyris from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. Finally, B. Riley set a $10.00 price target on shares of Amyris and gave the company a “buy” rating in a research report on Monday, September 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $8.83.

In related news, CFO Kathleen Valiasek bought 23,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 27th. The stock was bought at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the completion of the transaction, the chief financial officer now owns 251,630 shares of the company’s stock, valued at $1,099,623.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Eduardo Alvarez bought 11,877 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was bought at an average price of $8.45 per share, with a total value of $100,360.65. Following the completion of the transaction, the chief operating officer now directly owns 331,877 shares of the company’s stock, valued at approximately $2,804,360.65. The disclosure for this purchase can be found here. 21.80% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in AMRS. BlackRock Inc. grew its position in Amyris by 139.2% in the first quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after acquiring an additional 31,083 shares in the last quarter. Millennium Management LLC purchased a new position in Amyris in the first quarter worth $1,643,000. Engineers Gate Manager LP purchased a new position in Amyris in the second quarter worth $413,000. Rhumbline Advisers purchased a new position in Amyris in the second quarter worth $147,000. Finally, Bank of New York Mellon Corp grew its position in Amyris by 87.7% in the second quarter. Bank of New York Mellon Corp now owns 106,216 shares of the biotechnology company’s stock worth $678,000 after acquiring an additional 49,628 shares in the last quarter. Institutional investors own 28.87% of the company’s stock.

Shares of AMRS traded up $0.13 during mid-day trading on Friday, reaching $4.94. 991,429 shares of the stock traded hands, compared to its average volume of 1,713,172. The firm has a market capitalization of $355.24 million, a P/E ratio of -1.62 and a beta of 0.27. Amyris has a 1 year low of $3.11 and a 1 year high of $9.28.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Read More: Stock Split

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit